4BASEBIO UK SOCIETAS

4BASEBIO UK SOCIETAS

4BB · LSE · Healthcare / Biotechnology

525.00GBX+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close525.00
Open507.50
Day Range507.50 – 550.00
52-Week Range420.00 – 820.00
Volume569
Market Cap87.10M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.16
Dividend Yield0.00%
Beta0.86
50-Day Avg508.48
200-Day Avg525.37

About

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for use in vaccines and therapeutics; oeDNA, a linear, double stranded DNA for genome editing; osDNA, a DNA product that incorporates nucleotide modifications within the DNA backbone; and Hermes, a nanoparticle platform. The company also provides custom pegRNA and sgRNA manufacturing; and nanoparticle formulation services. Its products are used in mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines, and non-viral delivery applications. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and is headquartered in Cambridge, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Amy Jo Walker
  • Employees140
  • Headquarters25 Norman Way, Cambridge, United Kingdom, CB24 5QE, UK
  • Websitehttps://www.4basebio.com

Leadership

  • Dr. Manja Hermina Elisabeth Maria Boerman Ph.D.Executive Chair of the Board · b. 1966
  • Dr. Amy Jo WalkerCEO & Director · b. 1993
  • Dr. Heikki Lanckriet Ph.D.Founder, Technical Advisor & Non-Executive Director · b. 1977
  • Mr. Richard Edward Bungay A.C.A., B.Sc.Chief Financial Officer · b. 1969
  • Mr. Scott LorimerChief Operating Officer
  • Ms. Jennifer GelmanVice President of Marketing
  • Ms. Christine WolosinChief Commercial Officer

Financials

Income Statement

Currency: GBP2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue202.00K462.00K338.00K268.00K506.00K933.00K1.69M
Growth (%)-+128.71%-26.84%-20.71%+88.81%+84.39%+81.46%
Cost of Revenue230.00K188.00K69.00K29.00K166.00K303.00K1.15M
Gross Profit-28.00K274.00K269.00K239.00K340.00K630.00K548.00K
Gross Margin-13.86%59.31%79.59%89.18%67.19%67.52%32.37%
Operating Expense392.00K896.00K3.80M6.08M8.39M12.67M17.27M
Operating Income-420.00K-622.00K-3.53M-5.84M-8.05M-12.04M-16.73M
Operating Margin-207.92%-134.63%-1043.49%-2179.10%-1591.30%-1290.68%-988.01%
EBITDA-136.00K-346.00K-3.21M-5.41M-7.34M-10.97M-15.58M
EBITDA Margin-67.33%-74.89%-948.82%-2018.28%-1451.19%-1175.67%-920.38%
Net Income-423.00K-719.00K-3.23M-5.15M-7.67M-12.33M-16.91M
Net Income Margin-209.41%-155.63%-957.10%-1921.64%-1514.82%-1321.86%-998.52%
R&D241.00K343.00K1.62M2.08M3.56M4.68M5.12M
R&D as % of Total Revenue119.31%74.24%479.88%776.49%703.56%502.04%302.60%
Interest Expense109.00K94.00K113.00K89.00K302.00K752.00K887.00K
Interest Expense % of Total Revenue53.96%20.35%33.43%33.21%59.68%80.60%52.39%

Balance Sheet

Currency: GBP2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.16M17.81M14.70M11.69M11.92M44.73M29.55M
Total Liabilities3.04M2.35M3.01M4.57M12.41M18.35M19.44M
Total Equity-1.89M15.46M11.70M7.12M-492.00K26.38M10.11M
Cash80.00K15.00M9.59M4.35M3.07M34.60M17.80M
Total Debt2.59M1.72M1.76M3.35M10.46M15.22M16.50M
Net Debt2.51M-13.28M-7.83M-1.00M7.39M-19.39M-1.30M

Cash Flow

Currency: GBP2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-269.00K-1.02M-2.74M-4.70M-6.18M-10.74M-14.75M
Investing Cash Flow-203.00K1.45M-1.51M-1.94M-1.49M-1.57M-1.64M
Financing Cash Flow487.00K14.43M-467.00K1.24M6.42M43.87M-369.00K
Capital Expenditure203.00K849.00K1.51M1.94M1.49M1.57M458.00K
Free Cash Flow-472.00K-1.87M-4.25M-6.64M-7.67M-12.31M-15.21M
FCF to OCF175.46%183.07%155.18%141.26%124.12%114.62%103.10%

Earnings

Report DateSep 30, 2021Jun 9, 2022Sep 30, 2022May 11, 2023Sep 27, 2024May 30, 2025Sep 29, 2025Feb 25, 2026
EPS Estimate0.000.00--0.000.000.00-0.67
EPS Actual-0.13-0.13-0.20-0.22-0.45-0.49-0.500.00
Surprise-------100.00%
Timing--After-hoursAfter-hours----

Key Statistics & Ratios

Market Cap87.10M
Enterprise Value86.02M
Trailing P/E0.00
Forward P/E0.00
Price / Sales111.53
Price / Book8.61
EPS-1.16
Book Value0.651
Revenue (TTM)781.00K
Gross Profit (TTM)407.00K
EBITDA-16.30M
Profit Margin0.00%
Operating Margin-3385.88%
Return on Equity-177.98%
Return on Assets-33.60%
Shares Outstanding15.48M
Shares Float5.74M
Beta0.86
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%